Which they'll pay for in shares.. Maybe full dilution is what they're going for before FDA approval, then RSS right before approval and uplisting shortly after? Would be an interesting strategy. Market cap of $40m for a company with a $5m net loss is speculating heavily on approval and even then with an increase in $10-15m YoY in rev it doesn't justify a short term market cap much higher than current levels. I hate to say it but I think we all (myself included) have been played. Ill be long again if price resets and convertible debt decreases, but at current levels Im out unless someone can convince me otherwise... and trust me I want to be long.. GL to anyone sticking it out, I hope Im wrong.
News 
Market Data 
Discover 
